Maximizing the Benefit of Renin-Angiotensin Blocking Drugs in Diabetic Renal Disease.

Completed · Not applicable

Conditions studied: Diabetic Nephropathy

In brief

The angiotensin converting enzyme inhibitor drugs are now standard therapy for patients with diabetic nephropathy. The hypothesis of this study is that adding a diuretic agent (furosemide) will decrease the urine protein, which is a sign of disease, more than an angiotensin converting enzyme inhibitor alone.

Key facts

Study ID

NCT00240019

Run by

Stanford University

People needed

30

Starts

2003-12-01

Expected to finish

2006-04-01

Last updated by the study team

2006-10-17

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• proteinuria greater than 1 gram/day serum creatinine < 2.6 for men, < 2.0 for women

You may not qualify if…

• blood pressure which cannot be controlled without a diuretic renal diseases other than diabetic nephropathy other disease which would alter renal function during 6 months

Where it is running

• Kaiser Permanente of Northern California, Santa Clara and San Jose — Santa Clara, California, United States
• Stanford University Medical Center — Stanford, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.